Plain-English translation of NCT07423533 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether GenSci120, a new injectable medication, can help people with moderate to severe rheumatoid arthritis whose symptoms haven't improved with at least one other drug. Researchers will compare this medication at three different doses against a standard arthritis treatment and a placebo (inactive injection) to see which works best and is safest.
Many people with rheumatoid arthritis don't get enough relief from existing medications, and their joints continue to become damaged and painful. This study is trying to find out if this new treatment option can help patients whose disease hasn't responded well to other drugs already available.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic about 17 times over approximately 6 months. You'll receive either the new medication at one of three doses, a standard arthritis injection, or a placebo—given every 2 to 4 weeks depending on which group you're assigned to. At each visit, doctors will examine your joints, check your blood work, and ask how you're feeling to track whether the treatment is helping your arthritis.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
China